Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
LEGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.27 - $60.87
Previous CloseN/A
Volume249.07K
Average Volume (3M)1.25M
Market Cap
$5.89B
Enterprise Value$8.07B
Total Cash (Recent Filing)$286.75M
Total Debt (Recent Filing)$350.60M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 14, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding183,649,150
10 Day Avg. Volume1,434,896
30 Day Avg. Volume1,246,355
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.56
Enterprise Value/Ebitda-71.34
Forecast
1Y Price Target
$83.36Price Target Upside159.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Legend Biotech News
PremiumCompany Announcements
Legend Biotech’s Earnings Call: Growth and Expansion
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLegend expects meaningful growth in the second and third quarters from manufacturing step-ups at the new Raritan, New Jersey, site and the Novartis site initiating commercial production.
Market OpportunityThe 2L launch will continue to catalyze CARVYKTI growth, significantly increasing the market opportunity.
Product EfficacyCarvykti has shown an unprecedented overall survival benefit over standard of care therapies in relapsed refractory multiple myeloma.
Bears Say
Competitive LandscapeAnito-cel's slightly shorter median progression-free survival compared to Carvykti suggests a higher early relapse risk and potentially lower durability.
Regulatory RisksCommercial CARVYKTI story presents attractive buying opportunity amid risks associated with the changing FDA.
Safety ConcernsCRS remains the most concerning toxicity for BCMA-CART therapies like Carvykti.
---
Ownership Overview
―
Insiders
15.17% Mutual Funds
22.92% Other Institutional Investors
59.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $29.27 and its highest was $60.87 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $5.89B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is May 14, 2025 which is in 33 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Mar 11, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.247 by $0.317.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -0.21.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 183,649,150 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.247. Following the earnings report the stock price went up 9.286%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
---
Legend Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.36 (159.85% Upside)
$83.36 (159.85% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.62%
12-Months-Change
Fundamentals
Return on Equity
-15.45%
Trailing 12-Months
Asset Growth
-9.65%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation is a global biotechnology company focused on developing, manufacturing, and commercializing novel cell therapies for oncology and other indications. The company operates in the highly specialized sector of cell therapy, with its core product being CAR-T cell therapies aimed at treating various forms of cancer. Legend Biotech is headquartered in Somerset, New Jersey, and it has a significant presence in both the United States and China.
---
LEGN Company Deck
---
LEGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, market expansion, and improved financial performance for CARVYKTI. There were also significant advancements in manufacturing and pipeline development. However, some challenges remain, including supply constraints in Europe and ongoing efforts to address neurotoxicity. Overall, the positive aspects significantly outweigh the challenges.Read More>---
LEGN Stock 12 Month Forecast
Average Price Target
$83.36
▲(159.85% Upside)
Technical Analysis
Sarepta Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
BridgeBio Pharma
―
Revolution Medicines
―
Best Analysts Covering LEGN
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
-9.74%
reiterated a buy rating last month
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -9.74% per trade.
---